AOD9604
is a modified version of fragment 176-191, which is itself a
smaller, modified piece of rhuman growth hormone. AOD9604 was
originally developed as an anti-obesity drug due to its lipolytic
(fat burning) properties. This peptide is valued for the fact that
it has limited effects beyond fat burning. It does not appear to
affect IGF-1 levels or insulin levels and therefore is not a risk
factor in promoting glucose intolerance or diabetes. There is also
no evidence that the body forms antibodies against AOD9604 as it is
similar enough in structure to rHGH to avoid stimulating an immune
system response.